SNPMiner Trials (Home Page)
Report for Mutation A2143C
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 Helicobacter Pylori Eradication According to Sequencing-based 23S Ribosomal RNA Point Mutation Associated With Clarithromycin Resistance
The investigators investigated the point mutations in the 23S rRNA genes of patients infected with clarithromycin-resistant H. pylori and compared the H. pylori eradication rates based on the identified clinically significant point mutations.
NCT03884348 Helicobacter Pylori Infection Antibiotic Resistant Strain Drug: proton pump inhibitor, amoxicillin, clarithromycin Drug: proton pump inhibitor, amoxicillin, metronidazole MeSH:Sprains and Strains
Inclusion Criteria: - Clinical diagnosis of Helicobacter pylori infection Exclusion Criteria: - H. pylori eradication therapy within 1 year, - antibiotics within 4 weeks, - surgery for gastric cancer - malignant tumors other than gastric cancer - end-stage renal disease - liver cirrhosis, - pregnancy Inclusion Criteria: - Clinical diagnosis of Helicobacter pylori infection Exclusion Criteria: - H. pylori eradication therapy within 1 year, - antibiotics within 4 weeks, - surgery for gastric cancer - malignant tumors other than gastric cancer - end-stage renal disease - liver cirrhosis, - pregnancy Helicobacter Pylori Infection Antibiotic Resistant Strain Sprains and Strains Sequencing-based detection of point mutations identified four mutations that were considered clinically significant (A2142G, A2142C, A2143G, A2143C), while all the other mutations were considered clinically insignificant. --- A2142G --- --- A2142C --- --- A2143G --- --- A2143C ---
Primary Outcomes
Description: Number of participant with successful Helicobacter pylori eradication
Measure: Helicobacter pylori eradication rate Time: 2 year